Lignocainum Jelfa

Lidocaine, the active ingredient in Lignocainum Jelfa, is a local anesthetic presented as a sterile solution for urethral use. It provides reversible nerve impulse blockade to achieve temporary loss of sensation during urethral procedures in adult patients, and is intended for single‑use application by qualified healthcare professionals.

GNH USA supplies Lignocainum Jelfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lignocainum Jelfa, a lidocaine‑based local anesthetic, is used to provide anesthesia for procedures involving the urethral mucosa.

Urethral instrumentation: provides topical anesthesia to reduce discomfort during catheterization, cystoscopy, or urethral dilation. Urethral surgery: facilitates pain‑free operative field during transurethral resection or other surgical interventions. Urethral diagnostic procedures: enables patient tolerance during endoscopic evaluation of the urinary tract.

Common Side Effects: - Burning or stinging sensation at the application site. - Mild local irritation or erythema. - Transient numbness lasting beyond the procedure. - Dizziness or light‑headedness. - Taste disturbance if the solution contacts oral mucosa. - Mild hypotension in sensitive individuals.

Serious or Rare Side Effects: - Central nervous system toxicity (e.g., tinnitus, seizures, loss of consciousness). - Cardiac arrhythmias or conduction disturbances. - Severe allergic reaction (anaphylaxis, angioedema). - Methemoglobinemia leading to cyanosis. - Persistent numbness beyond expected duration. - Respiratory depression in cases of systemic absorption.

Before use, consider the following precautions: - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Dosage calculation: ensure administered volume does not exceed recommended maximum for urethral use. - Patient monitoring: observe for signs of systemic toxicity such as tinnitus, circumoral numbness, or seizures. - Concurrent medications: avoid simultaneous use with other sodium channel blockers. - Pregnancy and lactation: use only if the benefit outweighs the potential risk, as safety data are limited. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Lignocainum Jelfa may interact with other medicines. Review the following interactions:

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma levels and risk of toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise lidocaine concentrations. - Beta‑blockers (e.g., propranolol) when combined with high doses may potentiate central nervous system effects.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., carbamazepine): may reduce lidocaine efficacy. - Concurrent use of other local anesthetics: additive toxicity risk. - Loop diuretics (e.g., furosemide): may increase plasma lidocaine levels.